PE20090074A1 - DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) - Google Patents

DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)

Info

Publication number
PE20090074A1
PE20090074A1 PE2008000666A PE2008000666A PE20090074A1 PE 20090074 A1 PE20090074 A1 PE 20090074A1 PE 2008000666 A PE2008000666 A PE 2008000666A PE 2008000666 A PE2008000666 A PE 2008000666A PE 20090074 A1 PE20090074 A1 PE 20090074A1
Authority
PE
Peru
Prior art keywords
chloro
imidazol
pyridin
benzo
nitro
Prior art date
Application number
PE2008000666A
Other languages
English (en)
Inventor
Ralf Glatthar
David Carcache
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38654771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090074A1 publication Critical patent/PE20090074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (I) DONDE X1, X2, X3 Y X4 SON CADA UNO CR2 O N, EN DONDE R2 ES H, HALOGENO, NITRO, CN, FORMILO, ENTRE OTROS; R1 ES ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C12), ENTRE OTROS; B ES UN COMPUESTO DE FORMULA (B1), (B2), (B3) O (B4) EN DONDE Y1, Y2, Y3 E Y4 SON CADA UNO CR3 O N; Y5 E Y6 SON CADA UNO CR3 O N, DONDE R3 ES H, HALOGENO, HIDROXILO, NITRO, CARBOXILO, ENTRE OTROS; Y7 ES O, S O N(R3a), EN DONDE R3a ES H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), CICLOALQUILO(C3-C12), ENTRE OTROS; C ES UN SISTEMA DE ANILLO AROMATICO DE 5 A 12 MIEMBROS SUSTITUIDO CON Rb, EN DONDE Rb ES HALOGENO, NITRO, CN, FORMILO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [3-CLORO-5-(1-METIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-(4-CLORO-FENIL)-AMINA, [3-CLORO-5-(1-ETIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-(4-CLORO-FENIL)-AMINA, (4-CLORO-FENIL)-[3-CLORO-5-(1-PROPIL-1H-BENZO-IMIDAZOL-2-IL)-PIRIDIN-2-IL]-AMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) SIENDO UTILES EN EL TRATAMIENTO DE ISQUEMIAS CEREBRALES, ESPASMOS MUSCULARES, ENFERMEDAD DE REFLUJO GASTRO-ESOFAGICO, INCONTINENCIA URINARIA, HIPERPLASIA PROSTATICA BENIGNA
PE2008000666A 2007-04-19 2008-04-17 DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR) PE20090074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07106537 2007-04-19

Publications (1)

Publication Number Publication Date
PE20090074A1 true PE20090074A1 (es) 2009-03-02

Family

ID=38654771

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000666A PE20090074A1 (es) 2007-04-19 2008-04-17 DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)

Country Status (15)

Country Link
US (1) US20090105266A1 (es)
EP (1) EP2146969A1 (es)
JP (1) JP2010524892A (es)
KR (1) KR20090130141A (es)
CN (1) CN101679299A (es)
AR (1) AR068072A1 (es)
AU (1) AU2008240790A1 (es)
BR (1) BRPI0810653A2 (es)
CA (1) CA2682676A1 (es)
CL (1) CL2008001114A1 (es)
EA (1) EA200901379A1 (es)
MX (1) MX2009011208A (es)
PE (1) PE20090074A1 (es)
TW (1) TW200904425A (es)
WO (1) WO2008128968A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
WO2010135493A2 (en) * 2009-05-20 2010-11-25 Emory University Alzheimer's disease imaging agents
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
AU2012232711B2 (en) * 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
WO2013081094A1 (ja) * 2011-11-30 2013-06-06 東レ株式会社 イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CA2917262A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
CN107074846B (zh) 2014-08-12 2020-05-19 先正达参股股份有限公司 具有含硫取代基的杀有害生物活性杂环衍生物
ES2806598T3 (es) 2014-12-11 2021-02-18 Syngenta Participations Ag Derivados tetracíclicos activos como plaguicidas con sustituyentes que contienen azufre
TWI703133B (zh) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 ３,５-二胺基吡唑激酶抑制劑
ES2806459T3 (es) 2015-04-24 2021-02-17 Syngenta Participations Ag Derivados policíclicos activos como plaguicidas con heterociclos con anillos de cinco miembros sustituidos con azufre
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
WO2017001314A1 (en) 2015-07-01 2017-01-05 Syngenta Participations Ag Pesticidally active polycyclic derivatives with sulfur containing substituents
JP2018524337A (ja) 2015-07-01 2018-08-30 シンジェンタ パーティシペーションズ アーゲー 硫黄含有置換基を有する有害生物防除に活性な四環式誘導体
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
BR112018010347A2 (pt) 2015-11-23 2018-12-04 Syngenta Participations Ag derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e ciclopropila
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
SMT202100699T1 (it) 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
BR112019008492B1 (pt) 2016-10-27 2024-01-30 Syngenta Participations Ag Compostos derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e hidroxilamina, composição pesticida, método para controle de pragas e método para a proteção de material de propagação de plantas do ataque por pragas
WO2018091389A1 (en) 2016-11-17 2018-05-24 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
EP3554242A1 (en) 2016-12-15 2019-10-23 Syngenta Participations AG Pesticidally active heterocyclic derivatives with sulfur containing substituents
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
EP3562306B1 (en) * 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
WO2018215304A1 (en) 2017-05-22 2018-11-29 Syngenta Participations Ag Tetracyclic pyridazine sulphur containing compounds and their use as pesticides
EP3634420A1 (en) 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
CN110891949B (zh) 2017-07-05 2023-05-23 先正达参股股份有限公司 具有含硫取代基的杀有害生物活性杂环衍生物
EP3798212A4 (en) * 2018-05-22 2022-03-23 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, INSECTICIDE AND ACARICIDE FOR AGRICULTURE AND HORTICULTURE WITH THIS COMPOUND AND METHODS OF USE
PY1943991A (es) 2018-06-06 2020-03-09 Syngenta Crop Protection Ag Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
WO2019243523A1 (en) 2018-06-21 2019-12-26 Cellestia Biotech Ag Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
US20220185797A1 (en) * 2019-03-25 2022-06-16 The Trustees Of Columbia Universityin The City Of New York Selective foxo inhibitors for treatment of diabetes and other disorders related to impaired pancreatic function
BR112021020226A2 (pt) * 2019-04-10 2021-12-07 Cellestia Biotech Ag Inibidores de via de sinalização notch e uso dos mesmos no tratamento de cânceres
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
MX2022016546A (es) 2020-07-03 2023-02-01 Nihon Nohyaku Co Ltd Agente anticoccidio y metodo para su uso.
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN117396467A (zh) * 2021-06-02 2024-01-12 日本农药株式会社 苯并咪唑化合物或其盐类和包含该化合物的犬心丝虫病防治剂及其使用方法
WO2022255460A1 (ja) * 2021-06-02 2022-12-08 日本農薬株式会社 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
JP2025540259A (ja) * 2022-12-08 2025-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体
CN116332855B (zh) * 2023-04-04 2025-08-01 苏州美诺医药科技有限公司 一种crf1受体拮抗剂的苯并咪唑衍生物中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317266A2 (en) * 2000-08-08 2003-06-11 Ortho-McNeil Pharmaceutical, Inc. Neuroprotective 2-pyridinamine compositions and related methods
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
CA2555402A1 (en) * 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators

Also Published As

Publication number Publication date
AU2008240790A1 (en) 2008-10-30
EP2146969A1 (en) 2010-01-27
JP2010524892A (ja) 2010-07-22
US20090105266A1 (en) 2009-04-23
AR068072A1 (es) 2009-11-04
EA200901379A1 (ru) 2010-04-30
KR20090130141A (ko) 2009-12-17
TW200904425A (en) 2009-02-01
CA2682676A1 (en) 2008-10-30
CN101679299A (zh) 2010-03-24
CL2008001114A1 (es) 2008-12-19
MX2009011208A (es) 2009-10-30
BRPI0810653A2 (pt) 2014-11-04
WO2008128968A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
PE20090074A1 (es) DERIVADOS DE BENCIMIDAZOL COMO MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR)
PE20070489A1 (es) Compuestos derivados de sulfonamida como moduladores de glucoquinasa
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20090158A1 (es) Dihidro y tetrahidro oxazolopirimidinonas sustituidas y preparaciones de las mismas
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
EP2468725A4 (en) AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENE ELEMENTS THEREWITH
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
PE20081887A1 (es) Nuevo compuesto de adenina
PE20080278A1 (es) Compuestos de benzimidazolilo
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
UY31614A1 (es) Nuevos compuestos de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol y métodos de uso de los mismos.
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
PE20070978A1 (es) COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20091379A1 (es) Piridinil amidas para el tratamiento de transtornos del snc y metabolicos
AR069524A1 (es) Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
UY31436A1 (es) Nuevos compuestos tetracíclicos
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal